IN2014MN01809A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01809A
IN2014MN01809A IN1809MUN2014A IN2014MN01809A IN 2014MN01809 A IN2014MN01809 A IN 2014MN01809A IN 1809MUN2014 A IN1809MUN2014 A IN 1809MUN2014A IN 2014MN01809 A IN2014MN01809 A IN 2014MN01809A
Authority
IN
India
Prior art keywords
features
evaluating
test results
gastrointestinal cancer
target individual
Prior art date
Application number
Inventor
Nir Kalkstein
Yaron Kinar
Varda Shalev
Gabriel Chodick
Inbal Goldshtein
Original Assignee
Medial Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medial Res Ltd filed Critical Medial Res Ltd
Publication of IN2014MN01809A publication Critical patent/IN2014MN01809A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biophysics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Artificial Intelligence (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Theoretical Computer Science (AREA)
  • Physiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Software Systems (AREA)
  • Mathematical Physics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

A method of evaluating gastrointestinal cancer risk. The method comprises generating a set of features comprising a plurality of current blood test results from a blood collected from a target individual providing at least one classifier generated according to an analysis of a plurality of respective historical blood test results of each of another of a plurality of sampled individuals and evaluating using a processor a gastrointestinal cancer risk of the target individual by classifying the set of features using the at least one classifier.
IN1809MUN2014 2012-05-03 2013-05-02 IN2014MN01809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641979P 2012-05-03 2012-05-03
PCT/IL2013/050368 WO2013164823A1 (en) 2012-05-03 2013-05-02 Methods and systems of evaluating a risk of a gastrointestinal cancer

Publications (1)

Publication Number Publication Date
IN2014MN01809A true IN2014MN01809A (en) 2015-07-03

Family

ID=49514271

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1809MUN2014 IN2014MN01809A (en) 2012-05-03 2013-05-02

Country Status (13)

Country Link
US (3) US9474490B2 (en)
EP (1) EP2844131B1 (en)
JP (1) JP6267687B2 (en)
KR (1) KR102094326B1 (en)
CN (1) CN104271033B (en)
AU (1) AU2013255401B2 (en)
CA (1) CA2865892C (en)
ES (1) ES2655184T3 (en)
IN (1) IN2014MN01809A (en)
MX (1) MX347850B (en)
PL (1) PL2844131T3 (en)
RU (1) RU2640568C2 (en)
WO (1) WO2013164823A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094326B1 (en) 2012-05-03 2020-03-30 미디얼 리서치 리미티드 Methods and systems of evaluating a risk of a gastrointestinal cancer
US10614287B2 (en) 2014-06-16 2020-04-07 Siemens Healthcare Diagnostics Inc. Virtual staining of cells in digital holographic microscopy images using general adversarial networks
US10176363B2 (en) * 2014-06-16 2019-01-08 Siemens Healthcare Diagnostics Inc. Analyzing digital holographic microscopy data for hematology applications
US20160110516A1 (en) * 2014-10-20 2016-04-21 Liwei Ma Dynamic monitoring early cancer risk
CN104573410A (en) * 2015-01-20 2015-04-29 合肥工业大学 Cancer chemosensitivity prediction technique based on molecular subnet and random forest classifier
CN104615894B (en) * 2015-02-13 2018-09-28 上海中医药大学 A kind of Chinese Medicine Diagnoses System based on k neighbour's label certain weights features
CN106339569B (en) * 2015-07-09 2021-01-05 深圳迈瑞生物医疗电子股份有限公司 Method and device for judging sample test result abnormity
US10332638B2 (en) 2015-07-17 2019-06-25 Massachusetts Institute Of Technology Methods and systems for pre-symptomatic detection of exposure to an agent
JP6100867B1 (en) * 2015-11-06 2017-03-22 振武 曽 Test methods for analysis of immune status
CN109074420B (en) * 2016-05-12 2022-03-08 豪夫迈·罗氏有限公司 A system for predicting the effects of targeted drugs in treating diseases
US20180000428A1 (en) * 2016-05-18 2018-01-04 Massachusetts Institute Of Technology Methods and Systems for Pre-Symptomatic Detection of Exposure to an Agent
KR101747783B1 (en) * 2016-11-09 2017-06-15 (주) 바이오인프라생명과학 Two class classification method for predicting class of specific item and computing apparatus using the same
US20170140115A1 (en) * 2017-01-24 2017-05-18 Liwei Ma Intelligent stroke risk prediction and monitoring system
US20170147768A1 (en) * 2017-02-06 2017-05-25 Liwei Ma System and method for detecting and monitoring acute myocardial infarction risk
JP7431760B2 (en) * 2018-06-30 2024-02-15 ２０／２０ ジェネシステムズ，インク Cancer classifier models, machine learning systems, and how to use them
US12451248B2 (en) 2018-08-17 2025-10-21 The Regents Of The University Of California Diagnosing hypoadrenocorticism from hematologic and serum chemistry parameters using machine learning algorithm
CN109670526A (en) * 2018-11-09 2019-04-23 全球能源互联网研究院有限公司 A kind of interference source type discrimination method, device, equipment and the storage medium of power grid
EP3948286B1 (en) * 2019-03-28 2025-07-23 F. Hoffmann-La Roche AG Cancer prognosis
US20210299339A1 (en) * 2020-03-31 2021-09-30 Fresenius Medical Care Holdings, Inc. Blood monitoring system for determining a calibrated hemoglobin concentration value for a patient based on patient-specific mean corpuscular hemoglobin concentration data
TWI763215B (en) * 2020-12-29 2022-05-01 財團法人國家衛生研究院 Electronic device and method for screening feature for predicting physiological state
CN112735606B (en) * 2021-01-22 2023-04-25 张厚德 Colorectal cancer risk prediction method, device and storage medium
CN112908470B (en) * 2021-02-08 2023-10-03 深圳市人民医院 Hepatocellular carcinoma prognosis scoring system based on RNA binding protein gene and application thereof
CN112986446A (en) * 2021-04-19 2021-06-18 生态环境部华南环境科学研究所 Synchronous detection method and application of organic phosphate and metabolite in poultry egg products
GB202109560D0 (en) * 2021-07-01 2021-08-18 Chancellor Masters And Scholars Of The Univ Of Cambridge Anomaly detection based on complete blood counts
WO2023147472A1 (en) * 2022-01-28 2023-08-03 Freenome Holdings, Inc. Methods and systems for risk stratification of colorectal cancer
CN115620909B (en) * 2022-11-04 2023-08-04 内蒙古卫数数据科技有限公司 Cancer risk assessment system based on whole blood cell count fusion index HBI
CN117524464B (en) * 2024-01-04 2024-04-05 北京和兴创联健康科技有限公司 Method and system for calculating postoperative target hemoglobin based on big data

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5692220A (en) 1993-09-02 1997-11-25 Coulter Corporation Decision support system and method for diagnosis consultation in laboratory hematopathology
US6059724A (en) 1997-02-14 2000-05-09 Biosignal, Inc. System for predicting future health
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US7838296B2 (en) 2002-08-28 2010-11-23 Separation Technology, Inc. Methods and apparatus for ultrasonic determination of red blood cell indices
US20040122703A1 (en) * 2002-12-19 2004-06-24 Walker Matthew J. Medical data operating model development system and method
US7951078B2 (en) 2005-02-03 2011-05-31 Maren Theresa Scheuner Method and apparatus for determining familial risk of disease
WO2006102526A2 (en) 2005-03-22 2006-09-28 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Identification of biomarkers by serum protein profiling
WO2007016367A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Neoplastic disease-related methods, kits, systems and databases
JP5746811B2 (en) 2006-12-21 2015-07-08 味の素株式会社 Colorectal cancer evaluation method, colorectal cancer evaluation device, colorectal cancer evaluation method, colorectal cancer evaluation system, colorectal cancer evaluation program, and recording medium
JP5025371B2 (en) * 2007-07-31 2012-09-12 シスメックス株式会社 Blood analyzer
US8512240B1 (en) * 2007-11-14 2013-08-20 Medasense Biometrics Ltd. System and method for pain monitoring using a multidimensional analysis of physiological signals
US20100076787A1 (en) * 2008-09-11 2010-03-25 Stephen Naylor Method for preparing a medical data report
WO2010028658A1 (en) 2008-09-15 2010-03-18 Herlev Hospital, Region Hovedstaden Ykl-40 as a marker for gastrointestinal cancers
WO2010048282A1 (en) 2008-10-21 2010-04-29 Rothman Healthcare Research, Llc Methods of assessing risk based on medical data and uses thereof
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
JP2013511730A (en) 2009-11-23 2013-04-04 チルドレンズ メディカル センター コーポレーション Method for normalizing platelet biomarkers
KR102094326B1 (en) 2012-05-03 2020-03-30 미디얼 리서치 리미티드 Methods and systems of evaluating a risk of a gastrointestinal cancer

Also Published As

Publication number Publication date
US10452970B2 (en) 2019-10-22
CN104271033A (en) 2015-01-07
WO2013164823A1 (en) 2013-11-07
KR20150005909A (en) 2015-01-15
JP2015517653A (en) 2015-06-22
EP2844131A1 (en) 2015-03-11
RU2014140114A (en) 2016-06-20
CN104271033B (en) 2017-05-24
US20200050917A1 (en) 2020-02-13
PL2844131T3 (en) 2018-03-30
CA2865892C (en) 2021-08-24
US11651189B2 (en) 2023-05-16
KR102094326B1 (en) 2020-03-30
RU2640568C2 (en) 2018-01-09
EP2844131B1 (en) 2017-10-11
EP2844131A4 (en) 2015-11-18
US9474490B2 (en) 2016-10-25
US20170039334A1 (en) 2017-02-09
CA2865892A1 (en) 2013-11-07
JP6267687B2 (en) 2018-01-24
HK1205448A1 (en) 2015-12-18
ES2655184T3 (en) 2018-02-19
MX347850B (en) 2017-05-16
AU2013255401A1 (en) 2014-09-18
US20140235956A1 (en) 2014-08-21
AU2013255401B2 (en) 2017-02-23
MX2014011202A (en) 2014-11-21

Similar Documents

Publication Publication Date Title
IN2014MN01809A (en)
MX2016005825A (en) Methods and systems of evaluating a risk of lung cancer.
EP2899552A3 (en) Current detection structure
EP2882011A4 (en) SECONDARY BATTERY CONNECTION STRUCTURE, AND SECONDARY BATTERY APPARATUS COMPRISING SAME
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
IL244852B (en) Clinical outcome tracking and analysis
EP2863309A3 (en) Contextual graph matching based anomaly detection
EP2817729A4 (en) SPECTRAL MANAGEMENT ANALYSIS BASED ON THE CLOUD
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2013000776A (en) Systems and methods to analyze an immunoassay test strip comb member.
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
IL241496B (en) Method and system for analyzing biological specimens by spectral imaging
EP3239701A4 (en) Grazing incidence x-ray fluorescence spectrometer and grazing incidence x-ray fluorescence analyzing method
GB201102916D0 (en) Method of determination of tissue states by imaging mass spectrometry
GB2516329A (en) Method of electron beam diffraction analysis
EP2720217A3 (en) Method for swing result deduction and posture correction and the apparatus of the same
EP4234577A3 (en) Modified glycoproteins
EP3273217A4 (en) Specimen collection and separation instrument
Aguilar-Saavedra Heavy lepton pair production at LHC: Model discrimination with multi-lepton signals
EP3370323A4 (en) WIRING DIAGNOSTIC APPARATUS, BATTERY SYSTEM, AND ELECTRICAL SYSTEM
EP2660779A3 (en) Apparatus and method for generating image in positron emission tomography
GB2549194A (en) Techniques for display and processing of mass spectral data
GB2515713A (en) Methods, packaging and apparatus for collection of biological samples
EP2866879A4 (en) STIMULI GENERATOR, NEUROPROTHERTIC APPARATUS, AND STIMULATION METHOD
EP2760028A3 (en) Radiation generator, anti-scatter grid, and radiation imaging apparatus including at least one of the same